ADME-Toxicology > Activity & Kinetics Assays Products & Reviews

Immunogenicity assays are critical assessments that screen for potential anti‑drug antibodies (ADAs) and support product safety and efficacy. Prolytix supports partners with comprehensive immunogenicity method development, validation, and testing for preclinical and clinical phases of biotherapeutic development.

A focused set of recombinant immune regulatory proteins, such as PD-1, PD-L1, and CTLA-4, essential for research and drug discovery in cancer immunotherapy and autoimmunity.

Recombinant proteins specifically relevant as E3 ligases or target proteins for Proteolysis Targeting Chimeras (PROTACs), enabling the development of this novel targeted protein degradation technology.